← Back to headlines
Summit Stock Downgraded Following Merck Data Release for Sac-TMT
Summit's stock has been downgraded by H.C. Wainwright following the release of new data from Merck concerning its sac-TMT treatment.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
